- Zuclopenthixol
-
- $551.00
-
2026-08-26
- CAS:53772-83-1
- Purity: 99.96%
- Supply Ability: 10g
- Zuclopenthixol
-
-
2026-06-30
- CAS:53772-83-1
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1000kgs
|
| | Zuclopenthixol Basic information |
| | Zuclopenthixol Chemical Properties |
| Melting point | 56-60°C | | Boiling point | 577.4±50.0 °C(Predicted) | | density | 1.289±0.06 g/cm3(Predicted) | | storage temp. | -20°C Freezer, Under Inert Atmosphere | | solubility | Chloroform (Slightly), Methanol (Slightly) | | form | Solid | | pka | 14.96±0.10(Predicted) | | color | White to Off-White | | InChI | InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2/b18-5- | | InChIKey | WFPIAZLQTJBIFN-DVZOWYKESA-N | | SMILES | S1c2c(cc(cc2)Cl)\C(=C/CCN4CCN(CC4)CCO)\c3c1cccc3 | | CAS DataBase Reference | 53772-83-1 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | Zuclopenthixol Usage And Synthesis |
| Description | Zuclopenthixol is a dopamine receptor antagonist (Kis = 9.8 and 1.5 nM for D1 and D2 receptors, respectively). It also binds to serotonin (5-HT) receptor subtypes 5-HT2 and 5-HT6, α1-adrenergic, and histamine receptors (Kis = 7.6, 3, 33, and 169 nM, respectively) but not α2-adrenergic receptors (Ki = >4,300 nM). Zuclopenthixol inhibits dopamine-induced accumulation of cAMP in rat striatal homogenates (IC50 = 330 nM; Ki = 16 nM). It decreases stereotypic behavior induced by methylphenidate in mice (ED50 = 0.8 μmol/kg) and by apomorphine in rats and dogs (ED50s = 6.0 and 1.3 μmol/kg, respectively). Zuclopenthixol (0.7 and 1.4 mg/kg, i.p.) administered prior to testing enhances memory retrieval in rats in an inhibitory avoidance task without affecting locomotor activity. | | Description | Zuclopenthixol is a kind of antipsychotic agent. It is a thioxanthene-based neuroleptic with in vivo action similar to the phenothiazine antipsychotics through antagonizing D1 and D2 dopamine receptors. It has three major formulations form including zuclopenthixol decanoate, zuclopenthixol acetate, and zuclopenthixol dihydrochloride. It can be used for the treatment of schizophrenia and bipolar mania. Besides antagonizing the D1 and D2 dopamine receptors, Zuclopenthixol can also take effect through antagonizing alpha1-adrenergic and 5-HT2 receptors. It can also weakly block the histamine H1 receptor. | | Chemical Properties | Pale Yellow Low Melting Solid | | Uses | The cis(Z)-form of Clopenthixol. Thioxanthene neuroleptic. Antipsychotic. | | Uses | The labelled cis(Z)-form of Clopenthixol. Thioxanthene neuroleptic. Antipsychotic. | | Uses | Zuclopenthixol is an anti-psychotic drug. It is an inhibitor of coxsackievirus B3. Also, it is an intermediate used in the synthesis of Zuclopenthixol Decanoate (Z701490), which is used in the maintenance treatment of chronic schizophrenic patients. It is one of the three distinct formulations of Zuclopenthixol namely, zuclopenthixol dihydrochloride, zuclopenthixol acetate or Acuphase and zuclopenthixol decanoate. | | Definition | ChEBI: The (Z)-isomer of clopenthixol. | | Clinical Use | Antipsychotic for schizophrenia and other psychoses | | Drug interactions | Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effects.
Analgesics: increased risk of convulsions with
tramadol; enhanced hypotensive and sedative
effects with opioids; increased risk of ventricular
arrhythmias with methadone.
Anti-arrhythmics: increased risk of ventricular
arrhythmias with anti-arrhythmics that prolong
the QT interval - avoid with amiodarone and
disopyramide.
Antibacterials: increased risk of ventricular
arrhythmias with moxifloxacin and parenteral
erythromycin - avoid
Antidepressants: increased level of tricyclics; possible
increased risk of convulsions with vortioxetine.
Antiepileptics: anticonvulsant effect antagonised.
Antimalarials: avoid concomitant use with
artemether/lumefantrine.
Antipsychotics: avoid concomitant use of clozapine
with depot preparations in case of neutropenia;
possible increased risk of ventricular arrhythmias
with risperidone.
Antivirals: concentration possibly increased with
ritonavir.
Atomoxetine: increased risk of ventricular
arrhythmias.
Anxiolytics and hypnotics: increased sedative effects.
Beta-blockers: increased risk of ventricular
arrhythmias with sotalol - avoid.
Cytotoxics: increased risk of ventricular arrhythmias
with vandetanib - avoid; increased risk of ventricular
arrhythmias with arsenic trioxide. | | Metabolism | Metabolism of zuclopenthixol is by sulphoxidation, sidechain N-dealkylation and glucuronic acid conjugation.
The sulphoxide metabolites are mainly excreted in the
urine while unchanged drug and the dealkylated form
tend to be excreted in the faeces. | | References | https://www.drugbank.ca/drugs/DB01624
https://en.wikipedia.org/wiki/Tiabendazole |
| | Zuclopenthixol Preparation Products And Raw materials |
|